New daily pill shows promise for obesity and diabetes in early trial
NCT ID NCT05184322
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tested an oral tablet called ecnoglutide in 87 healthy adults. The drug is a GLP-1 analogue, similar to existing injectable treatments for type 2 diabetes and obesity, but designed to be taken by mouth. The main goal was to check safety and how the body processes the drug, not yet to measure weight loss or blood sugar control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ecnoglutide (a GLP-1 analogue)
What this could lead to
If successful, this could lead to a convenient daily pill for managing obesity and type 2 diabetes.
What could go wrong
This is a very early Phase 1 trial in healthy people, so safety and effectiveness are not yet known. Many early drugs fail to show benefit in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Q-Pharm Pty Ltd (AKA Nucleus Network Brisbane)
Herston, Queensland, 4006, Australia